| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 52
| Issue : 4 | Page : 587-589 |
Effect of dendritic cell vaccine therapy on lymphocyte subpopulation in refractory primary brain tumor
J Niu1, Y Chang1, X Lu2, X Wu3, Y Pang1
1 Department of Oncology, Institute of Oncology, Tianjin, China
2 Department of Oncology, Institute of Oncology, Tianjin; Department of Operation, Shanghai Claison Biotechnology Co. Limited, Shanghai, China
3 Department of Oncology, Institute of Oncology; Institute of Oncology, Tianjin Union Medicine Centre, Tianjin, China
Correspondence Address:
Y Pang
Department of Oncology, Institute of Oncology, Tianjin
China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0019-509X.178373
BACKGROUND: Dendritic cell (DC)-based immunotherapy has the potential to induce an antitumor response within the immunologically privileged brain. AIMS: The aim of this study was to evaluate the short-term effect of DC vaccine therapy on lymphocyte subsets in patients with refractory primary brain tumor. MATERIALS AND METHODS: Eighteen cases with refractory primary brain tumor who refused any treatment against tumor within 6 months of the therapy, were referred to one medicine center, from January 2011 to October 2012. All patients received 1 × 107 tumor lysate–pulsed DC vaccinations both intradermal injection and intravenous infusion 3 times/week. RESULTS: There were increases of lymphocytes CD8+ (P = 0.002) and CD56+ (P = 4.207E-10), but no change of lymphocytes CD3+ (P = 0.651). Six patients were positive response of delayed-type hypersensitivity. There were improving of appetite in 14 cases and increasing of physical strength 17 cases. CONCLUSIONS: DC vaccine has the potential for inducing an immune cytotoxic effect directed toward tumor cells.
[FULL TEXT] [PDF]*
|
